[go: up one dir, main page]

PT1086223E - Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações - Google Patents

Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações Download PDF

Info

Publication number
PT1086223E
PT1086223E PT99955273T PT99955273T PT1086223E PT 1086223 E PT1086223 E PT 1086223E PT 99955273 T PT99955273 T PT 99955273T PT 99955273 T PT99955273 T PT 99955273T PT 1086223 E PT1086223 E PT 1086223E
Authority
PT
Portugal
Prior art keywords
strap
family
prostate
human
expressed
Prior art date
Application number
PT99955273T
Other languages
English (en)
Inventor
Stephen Chappell Mitchell
Arthur B Raitano
Douglas C Saffran
Daniel E Afar
Rene S Hubert
Kahan Leong
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of PT1086223E publication Critical patent/PT1086223E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT99955273T 1998-06-01 1999-06-01 Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações PT1086223E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8752098P 1998-06-01 1998-06-01
US9118398P 1998-06-30 1998-06-30

Publications (1)

Publication Number Publication Date
PT1086223E true PT1086223E (pt) 2009-11-03

Family

ID=26777066

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99955273T PT1086223E (pt) 1998-06-01 1999-06-01 Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações

Country Status (13)

Country Link
US (10) US6329503B1 (pt)
EP (2) EP2080802B1 (pt)
JP (5) JP4855577B2 (pt)
AT (1) ATE437947T1 (pt)
AU (1) AU757698C (pt)
CA (1) CA2328989C (pt)
CY (1) CY1109509T1 (pt)
DE (1) DE69941187D1 (pt)
DK (1) DK1086223T3 (pt)
ES (2) ES2629442T3 (pt)
IL (2) IL139699A0 (pt)
PT (1) PT1086223E (pt)
WO (1) WO1999062941A2 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20020187472A1 (en) * 2001-03-09 2002-12-12 Preeti Lal Steap-related protein
US20040048798A1 (en) * 1999-06-01 2004-03-11 Raitano Arthur B. Nucleic acid and corresponding protein entitle 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) * 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
PT1086223E (pt) 1998-06-01 2009-11-03 Agensys Inc Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) * 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU5416700A (en) * 1999-05-20 2000-12-12 Fahri Saatcioglu Differentially expressed genes in prostate cancer
AU775366B2 (en) * 1999-12-06 2004-07-29 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU2001236807A1 (en) * 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7189565B2 (en) 2001-03-23 2007-03-13 Fahri Saatcioglu Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
AU2001249411B2 (en) * 2000-03-24 2007-02-15 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
ES2320421T3 (es) 2001-01-17 2009-05-22 Intreat Pty Limited Anticuerpos para el diagnostico de un receptor p2x7 no funcional y el tratamiento de canceres y otras afecciones.
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7494646B2 (en) * 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JP2005505271A (ja) * 2001-09-06 2005-02-24 アジェンシス, インコーポレイテッド 癌の処置および検出において有用なsteap−1と名称が与えられる核酸および対応するタンパク質
WO2003053357A2 (en) * 2001-12-19 2003-07-03 Wilk Patent Development Corporation Method and related composition employing nanostructures
CA2517027A1 (en) 2002-02-25 2003-09-04 Vaxiion Therapeutics, Inc. Minicell compositions and methods
US7906620B2 (en) * 2002-08-16 2011-03-15 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
JP5840351B2 (ja) * 2002-09-06 2016-01-06 アジェンシス,インコーポレイテッド 癌の処置および検出において有用な98p4b6と称される、核酸および対応タンパク質
PT1725249E (pt) * 2003-11-06 2014-04-10 Seattle Genetics Inc Compostos de monometilvalina capazes de conjugação a ligandos
SI1742966T1 (sl) * 2004-04-22 2014-03-31 Agensys, Inc. Protitelesa in iz njih izvedene molekule, ki se veĹľejo na STEAP-1 proteine
JP2009516757A (ja) * 2005-10-21 2009-04-23 メディバス エルエルシー ポリ(エステルウレア)ポリマーおよび使用法
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2008043145A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
CN111499748A (zh) 2007-07-16 2020-08-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
EP3388086B1 (en) 2007-08-17 2020-10-07 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
JP6126773B2 (ja) 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原(psca)抗体
US8293491B2 (en) 2007-09-14 2012-10-23 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
AU2008299593B2 (en) 2007-09-14 2013-04-18 Biosceptre International Limited Novel P2X7 epitopes
EP2740490A1 (en) * 2007-10-03 2014-06-11 Cornell University Treatment of proliferative disorders using antibodies to PSMA
ES2587392T3 (es) 2008-01-31 2016-10-24 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
NZ590146A (en) 2008-07-04 2012-09-28 Biosceptre Int Ltd Antibodies which bind an epitope comprising two different monomers of the P2X7 receptor
EP3495000A1 (en) 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP2966090B1 (en) 2009-08-20 2018-10-10 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
RU2673908C2 (ru) 2009-12-02 2018-12-03 Имэджинэб, Инк. Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения
ES2667003T3 (es) 2009-12-24 2018-05-09 Biosceptre (Aust) Pty Ltd Anticuerpos para receptores P2X7 oligoméricos no funcionales
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
SG185430A1 (en) 2010-06-03 2012-12-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
ES2656971T3 (es) 2010-09-10 2018-03-01 Biosceptre (Aust) Pty Ltd Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7
WO2012057765A1 (en) 2010-10-28 2012-05-03 The Board Of Regents Of The University Of Texas System Recombinant anti-cd19 monoclonal antibodies
AU2015261742B2 (en) * 2010-11-12 2017-10-26 Inovio Pharmaceuticals, Inc. Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
EP2638055B1 (en) * 2010-11-12 2019-01-09 The Trustees Of The University Of Pennsylvania Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
EP2675474B1 (en) 2011-02-15 2019-01-16 Vaxiion Therapeutics, LLC Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
EP2726095B1 (en) 2011-07-01 2018-06-06 Biosceptre (Aust) Pty Ltd Combination therapy
JP6219304B2 (ja) 2011-11-29 2017-10-25 ジェネンテック, インコーポレイテッド 前立腺癌分析のための組成物及び方法
KR20150104092A (ko) 2012-11-15 2015-09-14 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのn−ピペリジン−3−イルベンズアミド誘導体
KR101782623B1 (ko) 2013-07-10 2017-09-28 서울대학교산학협력단 복합 막횡단 단백질의 세포막외 펩타이드 항원 및 그의 용도
SI4095130T1 (sl) 2013-10-18 2024-05-31 Novartis Ag Označeni zaviralci za prostato specifičnega membranskega antigena (PSMA), njihova uporaba kot kontrastna sredstva in farmacevtska sredstva za zdravljenje raka prostate
AU2014348601A1 (en) 2013-11-14 2016-05-26 Endocyte, Inc. Compounds for positron emission tomography
RS60349B8 (sr) 2014-09-23 2022-10-31 Hoffmann La Roche Postupak upotrebe anti-cd79b imunokonjugata
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
HK1255483A1 (zh) 2015-06-15 2019-08-16 基因泰克公司 抗体和免疫结合物
JP7026613B2 (ja) 2015-08-07 2022-02-28 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
WO2017106806A1 (en) 2015-12-18 2017-06-22 Federica Cavallo COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
EA201990781A9 (ru) * 2016-09-23 2019-11-27 Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
MA46952A (fr) 2016-12-01 2019-10-09 Regeneron Pharma Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
AU2018247767B2 (en) * 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
WO2018204278A1 (en) 2017-05-01 2018-11-08 Agilvax, Inc. COMPOSITIONS AND METHODS RELATED TO xCT ANTIBODIES
CN110809583A (zh) 2017-06-07 2020-02-18 瑞泽恩制药公司 用于内化酶的组合物和方法
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CA3100021A1 (en) 2018-05-17 2019-11-21 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
PE20211091A1 (es) 2018-07-02 2021-06-14 Amgen Inc Proteina de union al antigeno anti-steap1
EP3823993A1 (en) * 2018-07-18 2021-05-26 Amgen Inc. Chimeric receptors to steap1 and methods of use thereof
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
WO1995014772A1 (en) 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
IL126314A (en) * 1996-03-25 2003-07-31 Northwest Biotherapeutics Inc Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma)
US5859045A (en) 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
EP0974057B1 (en) * 1996-07-15 2005-09-21 Mayo Foundation For Medical Education And Research Methods to detect hk2 polypeptides
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
DE19641560A1 (de) * 1996-10-09 1998-04-16 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen einen Komplex aus humanem ACT und einer Serinprotease
EP0953039B1 (en) 1996-10-15 2007-08-29 The Regents Of The University Of California Animal models of human prostate cancer progression
AU5243198A (en) 1996-10-30 1998-05-22 Uab Research Foundation, The Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク. 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CN1195851C (zh) 1997-02-25 2005-04-06 科里克萨有限公司 用于前列腺癌免疫疗法的化合物及其用途
ES2248891T3 (es) 1997-02-25 2006-03-16 Corixa Corporation Compuestos para inmunodiagnostico de cancer de prostata y metodos para su uso.
AU7592998A (en) * 1997-05-23 1998-12-11 Biogen, Inc. Modulators of tissue regeneration
PT1000146E (pt) 1997-08-01 2006-10-31 Serono Genetics Inst Sa Ests 5' para proteinas secretadas sem especificidade tecidular
JP2001512013A (ja) 1997-08-01 2001-08-21 ジェンセット 前立腺に発現される分泌タンパク質の5’est
JPH11164691A (ja) 1997-10-03 1999-06-22 Rikagaku Kenkyusho 胚盤胞cDNA
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6255049B1 (en) * 1998-02-27 2001-07-03 The Trustees Of Columbia University In The City Of New York Detection of metastatic cancer cells using PCTA-1
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
PT1086223E (pt) * 1998-06-01 2009-11-03 Agensys Inc Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
EP1140970A4 (en) 1998-12-17 2003-10-22 Human Genome Sciences Inc 47 HUMAN SECRETED PROTEINS
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
AU5457000A (en) 1999-06-11 2001-01-02 Human Genome Sciences, Inc. 48 human secreted proteins
AU6906800A (en) 1999-08-17 2001-03-13 Incyte Genomics, Inc. Membrane associated proteins
GB2354821A (en) 1999-09-29 2001-04-04 Dine O Quick Threshold crossing counter
AU7994200A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2391369A1 (en) 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU775366B2 (en) 1999-12-06 2004-07-29 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
WO2001051633A2 (en) 2000-01-14 2001-07-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001057190A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001057251A2 (en) 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
WO2001060860A2 (en) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
AU2001249411B2 (en) 2000-03-24 2007-02-15 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
CA2403909A1 (en) 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004509612A (ja) 2000-06-05 2004-04-02 アバロン ファーマシューティカルズ ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング
JP2004512022A (ja) 2000-06-09 2004-04-22 コリクサ コーポレイション 結腸癌の治療および診断のための組成物および方法
JP2004508019A (ja) 2000-07-28 2004-03-18 コンピュジェン インコーポレイテッド トランスクリプトームの中に場所を占めるrna転写物及びスプライス変異体を検出するためのオリゴヌクレオチドライブラリー
JP2004520806A (ja) 2000-08-24 2004-07-15 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
JP2005506033A (ja) 2000-10-13 2005-03-03 イーオーエス バイオテクノロジー インコーポレイテッド 前立腺癌の診断法、前立腺癌モジュレータースクリーニングの組成物及び方法
WO2002059260A2 (en) 2000-11-17 2002-08-01 Hyseq, Inc. Nucleic acids and polypeptides
WO2002057303A2 (en) 2001-01-12 2002-07-25 Hybrigenics Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
AU2002324424A1 (en) 2001-03-21 2002-12-03 Human Genome Sciences, Inc. Human secreted proteins
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
JP2005505271A (ja) 2001-09-06 2005-02-24 アジェンシス, インコーポレイテッド 癌の処置および検出において有用なsteap−1と名称が与えられる核酸および対応するタンパク質
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1308459A3 (en) 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
US6918525B2 (en) * 2003-05-23 2005-07-19 Worktools, Inc. Spring energized desktop stapler
SI1742966T1 (sl) 2004-04-22 2014-03-31 Agensys, Inc. Protitelesa in iz njih izvedene molekule, ki se veĹľejo na STEAP-1 proteine
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
US7056186B1 (en) * 2005-04-06 2006-06-06 Weyenberg Karey M Cleavage-enhancing foundation garment

Also Published As

Publication number Publication date
IL203524A (en) 2013-06-27
WO1999062941A3 (en) 2000-04-06
DE69941187D1 (de) 2009-09-10
WO1999062941A8 (en) 2000-08-03
US7611904B2 (en) 2009-11-03
US20070104720A1 (en) 2007-05-10
JP5683414B2 (ja) 2015-03-11
ES2329851T3 (es) 2009-12-01
EP1086223A2 (en) 2001-03-28
US7053186B2 (en) 2006-05-30
DK1086223T3 (da) 2009-11-30
US7575749B2 (en) 2009-08-18
JP6371362B2 (ja) 2018-08-08
US7928201B2 (en) 2011-04-19
WO1999062941A2 (en) 1999-12-09
EP1086223B1 (en) 2009-07-29
US7968307B2 (en) 2011-06-28
US20060147951A1 (en) 2006-07-06
CA2328989A1 (en) 1999-12-09
US20050202454A1 (en) 2005-09-15
WO1999062941A9 (en) 2000-09-14
US7642054B2 (en) 2010-01-05
EP2080802A2 (en) 2009-07-22
CY1109509T1 (el) 2014-08-13
JP2002517184A (ja) 2002-06-18
US8414898B2 (en) 2013-04-09
AU4326299A (en) 1999-12-20
JP4871341B2 (ja) 2012-02-08
US20110318371A1 (en) 2011-12-29
IL139699A0 (en) 2002-02-10
US6329503B1 (en) 2001-12-11
US20030055217A1 (en) 2003-03-20
US20030045682A1 (en) 2003-03-06
JP2017079748A (ja) 2017-05-18
EP2080802A3 (en) 2009-08-05
JP2014239695A (ja) 2014-12-25
JP2009106284A (ja) 2009-05-21
US20050064445A1 (en) 2005-03-24
JP2012050434A (ja) 2012-03-15
CA2328989C (en) 2012-02-07
EP2080802B1 (en) 2017-03-29
US20100173297A1 (en) 2010-07-08
JP4855577B2 (ja) 2012-01-18
AU757698B2 (en) 2003-03-06
AU757698C (en) 2004-04-08
US7166714B2 (en) 2007-01-23
US20100190962A1 (en) 2010-07-29
US6887975B2 (en) 2005-05-03
ES2629442T3 (es) 2017-08-09
ATE437947T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
IL139699A0 (en) Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
IL199275A0 (en) Serpentine transmembrane sntigens expressed in human prostate cancers and uses thereof
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
FI964766A0 (fi) Keuhkopintaproteiinin SP-C synteettiset peptidianalogit
CA2092533A1 (en) Nucleotide sequences coding for a human protein with angiogenesis regulative properties
MX336118B (es) Expresion hibrida y en tandem de proteinas de neisseria.
RU2002124123A (ru) Модифицированный фактор viii
TR200100074T2 (tr) Nevrotrofik büyüme faktörü
FR2649982B1 (fr) Membrane biologique artificielle
DE69535719D1 (de) Fas-antigenbindender ligand
ES2060803T3 (es) Soporte biologico para cultivos celulares constituido por proteinas plasmaticas coaguladas por trombina, su utilizacion para el cultivo de los queratinocitos, su recuperacion y su transporte con fines de utilizacion terapeutica.
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
DE60226896D1 (de) Herstellung von f(ab')2 fragmenten in saügetierzelle
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
WO2002022784A3 (en) Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
Niemčić Dance and Gender/Sex in the Lastovo Carnival
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
Niemčić The pokladarsko kolo on the island of Lastovo
ES8705466A1 (es) Un metodo para la preparacion del factor nkbs regulador del cancer humano.
WO2001082948A3 (en) Uses of tgap7 for the modulation of leucocyte activation
TR199900160T2 (xx) Immunoterapötik aktif maddeler olarak kullanışlı polipeptidler.
UA40172A (uk) Спосіб пластики вихідного тракту правого шлуночка і легеневої артерії при радикальній корекції тетради фалло